Johnson & Johnson Falls After Earnings, Vaccine Candidate Trial Pause

The equity is up over 14% year-over-year

Deputy Editor
Oct 13, 2020 at 11:09 AM
facebook X logo linkedin


Johnson & Johnson (NYSE:JNJ) is making waves this morning, after the company reported third-quarter earnings and revenue that topped Wall Street's estimates. Johnson & Johnson cited a faster-than-expected rebound in procedures utilizing its medical devices was a large factor in its quarterly beat, as well as a strong demand for its cancer drugs. However, separately, the company was forced to pause a clinical trial of its coronavirus vaccine candidate after a participant in the study came down with an unexplained illness. Johnson & Johnson stock is now down 1.7%, last seen trading at $149.24 this morning.

On the charts, JNJ is continuing its trend of trading sideways, plateauing after its late-April recovery and all-time high of $157. In fact, today's slip sent the equity back below $150 after spending the last two session above that territory. The 30-day moving average could provide some support moving forward, after acting as a rejection area in September, and for the year, JNJ boasts a 14.4% lead. 

Meanwhile, in the options pits, calls have been quite popular. In fact, JNJ sports a 50-day call/put volume ratio of 3.45 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which sits in the 82nd percentile of its annual range. Should this bullish sentiment begin to unwind, it could send the security lower.

Today's options pits are singing a slightly different tune. While over 14,000 calls have crossed the tape so far today, 10,000 puts have also exchanged hands -- eight times the intraday average and volume pacing in the 99th percentile of the last 12 months. Most popular by far is the October 155 call, followed by the 145 put from the same series. 

Now seems like a good time to weigh in on JNJ options, Johnson & Johnson stock's Schaeffer's Volatility Index (SVI) of 23% sits in just the 17th percentile of all other annual readings, meaning the equity sports attractively priced premiums at the moment.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI